On March 17, the National Comprehensive Cancer Network (NCCN) updated its 2026 Clinical Practice Guidelines to include ANKTIVA in combination with BCG. The treatment targets patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary-only disease. ImmunityBio (IBRX) is a commercial-stage immunotherapy company listed on NASDAQ.
